(continued)
- What Is Wegovy HD, and Why Does It Matter?
- Icotyde (icotrokinra): First Oral IL-23 Inhibitor for Plaque Psoriasis
- Wellcovorin (Leucovorin Calcium): First Approved Treatment for FOLR1-Related Cerebral Folate Transport Deficiency
- Sotyktu: FDA Approves First Selective, Once-Daily Oral TYK2 Inhibitor for Adults With Active Psoriatic Arthritis
- FDA Expands Palynziq to Adolescents
- Sogroya: Once-Weekly, Long-Acting Shot for Adults With Growth Hormone Deficiency and Children With Short Stature (GHD, SGA, Noonan Syndrome, ISS)
- Yuviwel (Navepegritide): Once-Weekly Shot to Help With Growth in Children With Achondroplasia
- Desmoda: FDA Approves the First and Only Liquid Version of Desmopressin to Ensure Precise Dosing in Patients With Central Diabetes Insipidus
- Loargys: FDA Approves the First and Only Injectable Enzyme Therapy, Paired With a Low‑Protein Diet, to Lower High Arginine Levels in Patients Ages 2 Years or Older With Arginase 1 Deficiency
- Adquey: FDA Approves New Nonsteroidal Ointment for Mild to Moderate Eczema
- Keytruda With Paclitaxel: FDA Approves New Combination Therapy for Certain Cancers Affecting the Ovaries, Fallopian Tubes, or Peritoneum
- Vybrique Gets FDA Nod as a First Oral Film for Treating Erectile Dysfunction
- Yuvezzi: First Combination Eye Drop for Age-Related Near Vision Loss
- Zycubo: FDA Approves First Under-the-Skin Shot for Treating Menkes Disease in Children
- Exdensur: FDA Approves New Twice-Yearly Medicine for Severe Asthma
- FDA Approves Lerochol: A Monthly Injectable Treatment to Reduce High LDL Cholesterol Levels in Adults
- Addyi: FDA Approves New Treatment for Low Sexual Desire in Postmenopausal Women
- Enhertu Plus Pertuzumab: New First-Line Option for Advanced HER2-Positive Metastatic Breast Cancer
- FDA Approves Blujepa: First New Oral Antibiotic for Gonorrhea in Decades
- FDA Approves Uplizna: A Twice-Yearly Targeted Therapy for Adults With Generalized Myasthenia Gravis
- Waskyra: First Gene Therapy for Wiskott-Aldrich Syndrome
- Omisirge: A New Cell Therapy for Severe Aplastic Anemia and Blood Cancers
- Epkinly: FDA Approves New Bispecific Antibody Option for Relapsed or Refractory Follicular Lymphoma
- Gazyva: FDA Approves Antibody-Based Infusion Therapy for Adults With Lupus Nephritis
- Tezspire: FDA Approves New Option for Chronic Sinus Inflammation With Nasal Polyps
- Rybelsus: FDA Approves the Only Oral GLP-1 Medicine to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes
- Uzedy: FDA Approves Once-a-Month Subcutaneous Injectable Risperidone for Bipolar I Disorder
- FDA Approves Palsonify: First Once-Daily Pill for Acromegaly in Adults
- Inluriyo: FDA Approves New Once-Daily Pill for ESR1-Mutated Advanced Breast Cancer in Patients Previously on Hormone Therapy
- Tremfya: First Fully Under-the-Skin IL-23 Inhibitor Shot Approved for Ulcerative Colitis and Crohn’s Disease